Cargando…
The State of the Heart Biopsy: A Clinical Review
Endomyocardial biopsy (EMB) is an invaluable and underused diagnostic tool for myocardial disease. The primary indications are surveillance of cardiac allograft rejection and the diagnosis of inflammatory and infiltrative cardiomyopathies. EMB is typically performed by sampling the right ventricular...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129478/ https://www.ncbi.nlm.nih.gov/pubmed/34027357 http://dx.doi.org/10.1016/j.cjco.2020.11.017 |
_version_ | 1783694297851232256 |
---|---|
author | Kiamanesh, Omid Toma, Mustafa |
author_facet | Kiamanesh, Omid Toma, Mustafa |
author_sort | Kiamanesh, Omid |
collection | PubMed |
description | Endomyocardial biopsy (EMB) is an invaluable and underused diagnostic tool for myocardial disease. The primary indications are surveillance of cardiac allograft rejection and the diagnosis of inflammatory and infiltrative cardiomyopathies. EMB is typically performed by sampling the right ventricular septum via the right internal jugular vein using fluoroscopic guidance. The diagnostic yield of EMB is improved by sampling both ventricles and with the use of guidance from imaging or electroanatomic mapping. The risk of major cardiac complications is operator dependent and < 1% in experienced centres. EMB is the gold standard and most common form of cardiac allograft rejection surveillance, whereas advanced cardiac imaging and donor-specific antibody quantification provide complementary information. Gene expression profiling is an alternative surveillance strategy to EMB for low-risk patients. EMB is recommended for myocarditis and can guide therapy for giant-cell myocarditis, necrotizing eosinophilic myocarditis, sarcoidosis, and immune checkpoint inhibitor myocarditis. There is growing interest in using EMB to guide therapy for viral myocarditis, although the uptake of this approach is limited to specialized centres. EMB has been replaced as a first-line test for infiltrative cardiomyopathy by nonbiopsy diagnostic techniques, but is still useful to clarify the diagnosis or disease subtype. The miniaturization of bioptomes and advances in laboratory techniques such as microarrays promises to improve the safety and yield of EMB. We review the contemporary use of EMB for cardiac allograft rejection, inflammatory cardiomyopathy, and infiltrative cardiomyopathy. |
format | Online Article Text |
id | pubmed-8129478 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-81294782021-05-21 The State of the Heart Biopsy: A Clinical Review Kiamanesh, Omid Toma, Mustafa CJC Open Review Endomyocardial biopsy (EMB) is an invaluable and underused diagnostic tool for myocardial disease. The primary indications are surveillance of cardiac allograft rejection and the diagnosis of inflammatory and infiltrative cardiomyopathies. EMB is typically performed by sampling the right ventricular septum via the right internal jugular vein using fluoroscopic guidance. The diagnostic yield of EMB is improved by sampling both ventricles and with the use of guidance from imaging or electroanatomic mapping. The risk of major cardiac complications is operator dependent and < 1% in experienced centres. EMB is the gold standard and most common form of cardiac allograft rejection surveillance, whereas advanced cardiac imaging and donor-specific antibody quantification provide complementary information. Gene expression profiling is an alternative surveillance strategy to EMB for low-risk patients. EMB is recommended for myocarditis and can guide therapy for giant-cell myocarditis, necrotizing eosinophilic myocarditis, sarcoidosis, and immune checkpoint inhibitor myocarditis. There is growing interest in using EMB to guide therapy for viral myocarditis, although the uptake of this approach is limited to specialized centres. EMB has been replaced as a first-line test for infiltrative cardiomyopathy by nonbiopsy diagnostic techniques, but is still useful to clarify the diagnosis or disease subtype. The miniaturization of bioptomes and advances in laboratory techniques such as microarrays promises to improve the safety and yield of EMB. We review the contemporary use of EMB for cardiac allograft rejection, inflammatory cardiomyopathy, and infiltrative cardiomyopathy. Elsevier 2020-12-01 /pmc/articles/PMC8129478/ /pubmed/34027357 http://dx.doi.org/10.1016/j.cjco.2020.11.017 Text en © 2020 Canadian Cardiovascular Society. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Kiamanesh, Omid Toma, Mustafa The State of the Heart Biopsy: A Clinical Review |
title | The State of the Heart Biopsy: A Clinical Review |
title_full | The State of the Heart Biopsy: A Clinical Review |
title_fullStr | The State of the Heart Biopsy: A Clinical Review |
title_full_unstemmed | The State of the Heart Biopsy: A Clinical Review |
title_short | The State of the Heart Biopsy: A Clinical Review |
title_sort | state of the heart biopsy: a clinical review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129478/ https://www.ncbi.nlm.nih.gov/pubmed/34027357 http://dx.doi.org/10.1016/j.cjco.2020.11.017 |
work_keys_str_mv | AT kiamaneshomid thestateoftheheartbiopsyaclinicalreview AT tomamustafa thestateoftheheartbiopsyaclinicalreview AT kiamaneshomid stateoftheheartbiopsyaclinicalreview AT tomamustafa stateoftheheartbiopsyaclinicalreview |